<DOC>
	<DOCNO>NCT02559193</DOCNO>
	<brief_summary>The Study single-arm prospective trial patient receive least one medication know association genetics drug metabolism . All patient undergo genetic testing determine treat physician . The specific gene test , general , base upon drug patient take patient 's treat physician consider potential substitute current medication .</brief_summary>
	<brief_title>Pharmacogenetic Testing Medication Management .</brief_title>
	<detailed_description>In data collection trial design , PGx test protocol-specified procedure . Rather , patient eligible undergone PGx test within last 90 day . Thus , PGx test perform solely inclusion clinical research initiative .</detailed_description>
	<criteria>1 . Patient underwent PGx test allele appropriate target drug within prior 90 day ( `` index PGx test '' ) ; 2 . Male female patient 18 year old give write Informed Consent participate Clinical Study base voluntary agreement explanation patient 's participation provide . Patients must adequate reading write ability comprehend answer question patient complete assessment Informed Consent Form ; 3 . Patient receive least one medication know associate allelic variation time index PGx test ) , include overthecounter medication ; 5 . Patient history least one TDAE 12month period precede receipt PGx test result , experienced inadequate efficacy target drug receive medical coverage private insurance . 1 . Patient currently hospitalize ; 2 . Patient 's medical medication history unavailable 90day period precede receipt PGx testing ; 3 . Patient unable provide accurate history due mental incapacity ; 4 . Patient known undergone prior PGx test gene specific target drug ( ) , exclusive PGx test relating Study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>